Bio-ARROW - SmartForm - Nanoparticles
Bio-ARROW - SmartForm - Nanoparticles
Bio-ARROW help
Nanoparticles are being used more frequently in biological research and present unique hazards. Nanoparticles are 1-100 nm, but ultrafine particles, tubules, and fibers up to 500 nm are often included in this category.
Nanoparticles used in association with or in biological materials need to be listed on a biosafety protocol (e.g., nanoparticles administered to cells/organs). If you are using nanoparticles or nanomaterials not in conjunction with biological materials, they need to be in your chemical hygiene plan but do not need to be listed on a biosafety protocol (e.g., purified proteins, chemicals, antibodies, drug delivery). Nanoparticles used in association with biological toxins need to be listed on a biosafety protocol.
The biological material or microbe used, in conjunction with the nanoparticle or nanomaterial, will determine the biosafety level for the activities. Nanoparticles or nanomaterials alone (not associated with biological materials) will not have a biosafety level designation, so the biosafety level will be determined based on the biological work.
More information on nanoparticles may be found at https://ehs.wisc.edu/workplace-safety/occupational-health/workplace-hazards/nanomaterial-usage-in-research-guidance/.
In addition to the nanoparticle specific page in Bio-ARROW, you will need to add additional information in other sections of the biosafety protocol.
|
Nanoparticle Name |
poly(D,L-lactide-co-glycolide) (PLGA) 100 nanometers |
|---|---|
|
Source |
Purchased |
|
Source Other |
No Value Entered |
|
Source More Than One |
No Value Entered |
|
Components |
Plasmid DNA encoding a miRNA, Poly lactic-co-glycolic acid (PLGA) |
|
Preparation Steps |
Receive 100 ul of nanoparticle ready-to-use, aliquot as used. Typically, less than 10 ul is used at a time. No dilution is needed. Plasmid is added and mixed before administration to cells. No containment is needed although a BSC may be used. |
|
Use of Final Product |
Administered to human cells |
|
Mode of Action |
Nanoparticle will deliver chemical drug promoting cellular uptake of ligands |
|
Administered To |
Administered to cells or cell cultures |
|
Administered To Other |
No Value Entered |
|
Additional Information |
FDA approved for human use |
|
Biosafety Level |
BSL1 |
|
Biosafety Level Other |
No Value Entered |
|
Storage Only |
No Value Entered |
|
Nanoparticle Name |
Lipid-based CRISPR nanoparticle |
|
Source |
Created in our lab |
|
Source Other |
No Value Entered |
|
Source More Than One |
No Value Entered |
|
Components |
Nanoparticle is lipid-based and encapsulates CRISPR components including Cas9 protein (active), homology directed repair template (DNA), and guide RNA (gRNA) and it directly targets the nucleus and delivers gene editing components |
|
Preparation Steps |
Human cancer cells lines will be treated with hypotonic lysing buffer, the resulting solution will undergo three freeze-thaw cycles, and then the mixture will be centrifuged to collect the cell membranes. |
|
Use of Final Product |
Nanoparticle administered by injection. Injections performed in a BSC. |
|
Mode of Action |
Delivery of cancer drugs to mouse tumor models. |
|
Administered To |
Administered to animals |
|
Administered To Other |
No Value Entered |
|
Additional Information |
No Value Entered |
|
Biosafety Level |
BSL2 |
|
Biosafety Level Other |
No Value Entered |
|
Storage Only |
No Value Entered |
Still have questions? Call the Office of Biological Safety (OBS) at 608-263-2037. We are happy to help you.